Sino-Japanese NK Cell Technology Strategic Cooperation

Jointly established a "NK Cell Adoptive Immunotherapy" joint laboratory with Odaka Hospital (Japan), focusing on the transformation of tumor immunotherapy technology and the standardization of clinical application.

Sino-US Frontier Exploration in Cell Therapy

Jointly established a global stem cell R&D center with Yale University to promote breakthroughs in regenerative medicine technology.
Cooperated with the National Institutes of Health (NIH, US) to carry out research o

Ocular Cranial Pressure Instability Disease Diagnosis and Treatment Technology Research Center

Jointly with Peking University Third Hospital and Henan Academy of Medical Sciences, undertook the national key R&D program of "ocular cranial pressure instability disease diagnosis and treatment technology", and developed an integrated solution for preci

Gene Engineering and Cell Therapy Joint R&D Platform

Jointly established a joint R&D platform with Tashkent Medical Academy, and promoted the development of breakthrough therapies combining CRISPR gene editing technology and cell therapy as a "the Belt and Road" project.

New Path for Stroke Treatment

Cooperated with Xuanwu Hospital of Capital Medical University to carry out the project of "mesenchymal stem cell-derived exosomes for the treatment of acute ischemic stroke", opening up a new strategy for nerve repair.

Innovation in Tumor Targeted Therapy Technology

Department of Plastic and Reconstructive Surgery, PLA General Hospital: Developed a stem cell exosome-targeted drug delivery system.
Ocular Oncology Department, Beijing Tongren Hospital: Led the IIT clinical research

Clinical Verification of TILs Therapy

Provided clinical-grade cell products for the IIT research on adjuvant treatment after pancreatic cancer surgery carried out in cooperation with Peking Union Medical College Hospital.

TCR-T Cell Therapy Revolution

Cooperated with the 7th Medical Center of the PLA General Hospital to develop a multi-target Hi-TCR-T technology targeting CLL1/NKG2DL/FAP, overcoming the drug resistance problem in childhood acute myeloid leukemia.

Cooperated with the 7th Medical Center of the PLA General Hospital to carry out research on NK cell therapy for HCMV infection after allogeneic hematopoietic stem cell transplantation in children, and built a new system of transplantation immunotherapy.